copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Alkermes | Cafepharma Facing the fact that Lundbeck’s unexpected offer for Avadel Pharmaceuticals was sweeter, Alkermes has come back to the negotiating table with a higher bid it believes can seal the deal Alkermes and Avadel have reached an accord on a new offer that would see Alkermes pay up to $22 50 per Avadel share to acquire the company, according to a Nov 19 press release The upgraded bid features $21
Lundbeck | Cafepharma Lundbeck is making a big push on the company’s capital reallocation initiative, handing over its operations in 27 markets to partners Lundbeck will transition to a partnership model in 27 markets through collaborations with the Swixx Group, Zuellig Pharma and NewBridge Pharmaceuticals, the Danish pharma said Tuesday
Chelsea Therapeutics | Cafepharma Chelsea Therapeutics Lundbeck Completes Acquisition of Chelsea Therapeutics; NORTHERA™ (droxidopa) is expected to be available to patients in the U S during the fall of this year Submitted by admin on Tue, 06 24 2014 - 10:26
Cafepharma - Home | pharma sales, device sales, lab sales | Cafepharma CDC advisers vote to overturn decades-long policy on hepatitis B vaccine for infants Pharma Biotech General Discussion board Eisai still confident in anti-tau asset as J J becomes latest victim in spiraling space Eisai board BMS's Breyanzi is first CAR-T for marginal zone lymphoma Bristol Myers Squibb board CHS sells lab assets to Labcorp for $194M LabCorp board *please scroll down for all the
Avadel Pharmaceuticals | Cafepharma Facing the fact that Lundbeck’s unexpected offer for Avadel Pharmaceuticals was sweeter, Alkermes has come back to the negotiating table with a higher bid it believes can seal the deal Alkermes and Avadel have reached an accord on a new offer that would see Alkermes pay up to $22 50 per Avadel share to acquire the company, according to a Nov 19 press release The upgraded bid features $21
November 14 2025 - Merck pays $9. 2B for Cidara, picking up flu . . . Merck pays $9 2B for Cidara, picking up flu antiviral spurned by J J Merck board Pfizer reportedly planning to divest BioNTech stake Pfizer board BMS and J J's blood thinner flunks phase 3, denting big blockbuster hopes Bristol Myers Squibb board, JNJ board Lundbeck makes bid for Avadel, trying to displace Alkermes Lundbeck board, Alkermes board *please scroll down for all the latest news
Abilify | Cafepharma Now, stepping to the plate with another long-acting treatment are Otsuka and Lundbeck On Thursday, the FDA signed off on Abilify Asimtufii, an extended-release, injectable suspension administered every two months The drug is for treating adults with schizophrenia and for maintenance in adults with bipolar I disorder Source Fierce Pharma Headline
August 15 2025 - Pfizer sickle cell drug fails trial | Cafepharma Amgen board Lundbeck dials up migraine drug's US peak sales estimate, stays positive on Rexulti's PTSD use Lundbeck board Eli Lilly endorses Trump's goal of aligning US, international drug prices
antidepressants | Cafepharma The end of an era is nearing for Lundbeck After a 17-year collaboration with Takeda on depression drug Trintellix, the Danish drugmaker is passing over its U S rights to its partner Effective January 1 of next year, Lundbeck will collect only royalties on the med in the U S market after switching from their current arrangement, which features shared promotion efforts, costs and revenues as